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The Nijmegen Biomedical Study is a population-based
cross-sectional study conducted in the eastern part of the
Netherlands. As part of the overall study, we provide
reference values of estimated glomerular filtration rate (GFR)
for this Caucasian population without expressed risk.
Age-stratified, randomly selected inhabitants received a
postal questionnaire on lifestyle and medical history. In a
large subset of the responders, serum creatinine was
measured. The GFR was then measured using the
abbreviated Modification of Diet in Renal Disease (MDRD)
formula. To limit possible bias, serum creatinine was
calibrated against measurements performed in the original
MDRD laboratory. The study cohort included 2823 male and
3274 female Caucasian persons aged 18–90 years. A reference
population of apparently healthy subjects was selected by
excluding persons with known hypertension, diabetes,
cardiovascular- or renal diseases. This healthy study cohort
included 1660 male subjects and 2072 female subjects,
of which 869 of both genders were 65 years or older.
The median GFR was 85 ml/min/1.73 m2 in 30–to 34-year-old
men and 83 ml/min/1.73 m2 in similar aged women.
In these healthy persons, GFR declined approximately
0.4 ml/min/year. Our study provides age- and gender-specific
reference values of GFR in a population of Caucasian
persons without identifiable risk.
Kidney International (2007) 72, 632–637; doi:10.1038/sj.ki.5002374;
published online 13 June 2007
KEYWORDS: population-based study; GFR; kidney function; MDRD
In recent years, chronic kidney disease (CKD) has received
increasing attention.1 Patients with CKD are at increased risk
for cardiovascular morbidity and mortality.2 Furthermore,
patients with CKD may progress to end-stage renal disease.3
As early treatment of patients with CKD may reduce
cardiovascular risk and delay the onset of end-stage renal
disease, it is important to identify patients with CKD in an
early stage.4 To increase the awareness of CKD and improve
treatment of patients with CKD, the Kidney Disease
Outcomes Quality Initiative (K/DOQI) from the US National
Kidney Foundation has developed guidelines for the
diagnosis and classification of CKD.5 K/DOQI has proposed
to classify CKD in five stages according to the absence or
presence of albuminuria and the level of the glomerular
filtration rate (GFR). The guidelines propose that patients
with GFR o60 ml/min/1.73 m2 are at risk and need to be
evaluated and properly treated.
Classification of patients with CKD thus necessitates
accurate assessment of GFR. For many years, serum
creatinine has been used in routine clinical practice as a
marker of GFR. It is well recognized that serum creatinine
is not an accurate marker of GFR.6 Serum creatinine is
dependent on muscle mass and the relation with GFR is
influenced by age, gender, and body weight. Therefore,
formulas have been developed for the estimation of GFR.
The K/DOQI guidelines advocate to use the recently
developed ‘Modification of Diet in Renal Disease
(MDRD)’-formula for the calculation of GFR. This formula
was derived from the MDRD study, which included patients
with renal disease, in whom GFR was measured with
an accurate, invasive technique using subcutaneous admin-
istration of Iothalamate.7 This formula provides a good
estimate of GFR, in particular, in the GFR range o60 ml/
min/1.73 m2.8,9 It is important to realize that for correct
reporting of MDRD-GFR attention must be given to
calibration of the creatinine assay against the creatinine assay
that was originally used in the original MDRD laboratory.10
The importance hereof was recently stipulated by a working
group.11
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Many laboratories have adopted this formula and have
started automated reporting of calculated MDRD-GFR.12 It
was recently shown that automated reporting of GFR indeed
leads to earlier identification of patients with CKD.13
However, reference values of estimated GFR are virtually
lacking. Lack of reference values for estimated GFR hampers
the interpretation of reported MDRD-GFR by medical
laboratories. Therefore, we have estimated GFR using the
MDRD formula for participants of the Nijmegen Biomedical
Study. We have calibrated the creatinine assay against the
MDRD laboratory. Our data provide reference values of
estimated GFR for a Caucasian population.
RESULTS
Age- and gender-specific reference values of GFR
Values of estimated GFR per 5-year age groups are given for
men and women in Tables 1a and 1b and 2a and 2b. In
Table 1a and 1b, data are given for the disease-free population.
Reference values for this ‘healthy’ population are depicted in
Figures 1 and 2. The data in Table 2a and 2b are based on the
results obtained in the population with reported comorbidities.
Stages of CKD
We have used the definitions of the K/DOQI. These
definitions require information on proteinuria or hematuria
to classify persons as CDK stage 1 or 2. Thus, our data only
allow correct classification of persons in stage 3 and above.
Figure 3 depicts the prevalence of CKD stage 3–5 (GFR
o60 ml/min/1.73 m2) in our population of disease-free
subjects. As expected, the prevalence increases with age,
reaching 42% in men and 44% in women of age 85 and
higher.
DISCUSSION
Our data provide reference values for MDRD-GFR using data
of an apparently healthy Caucasian population. We have used
the abbreviated MDRD equation that is nowadays most
regularly used. The MDRD formula provides the best
estimate of GFR, particularly in the range of GFR o60 ml/
min/1.73 m2.8,9 Awareness of CKD has increased in the past
decade. Especially, the publication of guidelines by the
K/DOQI from the National Kidney Foundation has fostered
interest in CKD worldwide.5
Table 1a | Estimated GFR in non-diseased caucasian males of the Nijmegen Biomedical Study
Age (years) N Mean7s.d. Range P5 P25 P50 P75 P95
18–24 94 100713 72–137 77 90 99 109 121
25–29 96 93713 67–125 74 82 90 102 117
30–34 118 86713 63–133 68 77 85 93 107
35–39 125 85714 61–118 65 74 85 95 110
40–44 143 84713 54–124 66 76 83 92 106
45–49 160 83713 50–123 63 73 82 91 105
50–54 143 79712 46–120 60 71 78 87 97
55–59 158 76713 27–118 58 68 75 84 98
60–64 149 75715 48–199 59 67 73 83 95
65–69 154 75714 51–165 56 66 74 82 97
70–74 102 71712 38–102 54 64 70 79 92
75–79 112 70713 41–110 45 62 70 79 91
80–84 73 67715 41–129 43 58 69 77 87
485 33 62716 34–101 35 47 65 72 92
GFR, glomerular filtration rate.
Values are given as means (s.d.), ranges and 5th, 25th, 50th, 75th, and 95th percentile.
Table 1b | Estimated GFR in non-diseased females of the Nijmegen Biomedical Study
Age (years) N Mean7s.d. Range P5 P25 P50 P75 P95
18–24 187 91715 58–186 72 80 90 99 112
25–29 159 85713 55–140 63 76 83 93 107
30–34 171 85715 53–153 63 74 83 93 113
35–39 193 79713 55–165 63 72 76 85 102
40–44 195 77712 48–117 58 67 77 84 100
45–49 227 74710 47–109 56 67 74 81 91
50–54 191 73713 51–152 56 64 71 79 93
55–59 174 70712 48–149 53 63 69 76 89
60–64 180 68712 41–148 50 61 68 75 84
65–69 156 66710 44–102 52 60 65 71 85
70–74 95 66711 40–96 49 58 64 73 85
75–79 77 62711 37–100 45 54 61 69 82
80–84 40 64714 46–114 46 56 62 73 88
485 27 59714 30–87 36 48 61 69 78
GFR, glomerular filtration rate.
Values are given as means (s.d.), ranges and 5th, 25th, 50th, 75th, and 95th percentile.
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The K/DOQI guidelines have proposed a classification
scheme, and defined five stages of CKD according to the
presence of proteinuria and the level of GFR. Patients with
GFRo60 ml/min/1.73 m2 (stages 3 and higher) are consid-
ered to be at high risk for cardiovascular morbidity,
mortality, and end-stage renal disease and should receive
special attention, directed at the identification and treatment
of cardiovascular risk factors. Many reports have recently
been published describing the prevalence of CKD in various
populations.14–16
However, these figures must be interpreted with caution.
First, most studies have calculated GFR using uncalibrated
creatinine assays.14–16 The importance of proper calibration
of the creatinine assays has recently been stressed.17,18 The
impact of the differences in creatinine assays is illustrated in a
recent study. Clase et al.16 calculated the prevalence of CKD
in a non-diabetic US population using data from National
Health and Nutrition Examination Survey III. Using
uncalibrated creatinine, they noted a 26.7% prevalence of
CKD stages 3–5 in 60- to 69-year-old Caucasian men. This
figure dropped to 7.4% when using calibrated creatinine.19,20
Most studies published in recent years are flawed by the use
of improper creatinine values.
Secondly, K/DOQI guidelines do not take age in account
when classifying patients. As GFR decreases with age, the
number of persons with CKD stages 3–5 (diseased) increases
with age, as shown by many investigators and as illustrated in
Figure 3. However, our data indicate that the 60 ml/min/
1.73 m2 cannot be used to define a diseased population. Our
reference values illustrate that MDRD-GFR decreases with
age. A GFR of 60 ml/min/1.73 m2 is within the normal
reference range for men 460 years and women 450 years.
Our data suggest that recommendations to define kidney
disease must be changed. In a recent study, the use of a
threshold value of 60 ml/min/1.73 m2 independent of age was
also questioned.21 Using a database of the VA system in the
US containing creatinine data of predominantly male
persons, it was shown that a GFR of 50–59 ml/min/1.73 m2
was associated with an increased mortality risk only in
younger persons (age 18–54 years). For older persons, GFR
Table 2a | Estimated GFR in caucasian males with reported comorbidity of the Nijmegen Biomedical Study
Age (years) N Mean7s.d. Range P5 P25 P50 P75 P95
18–24 1 — — — — 77 — —
25–29 8 — 15–128 — — 86 — —
30–34 4 — 74–107 — — 98 — —
35–39 15 86712 69–106 69 78 81 98 106
40–44 29 81717 13–118 63 75 83 88 98
45–49 39 78714 53–135 54 70 77 85 102
50–54 66 76714 50–107 52 66 75 86 97
55–59 100 76713 30–108 58 68 75 86 98
60–64 150 71714 42–106 50 61 71 80 98
65–69 182 68715 6–112 44 59 69 78 89
70–74 194 66715 25–112 40 58 66 76 91
75–79 180 62715 23–105 36 53 62 73 84
80–84 150 60716 15–102 31 48 61 72 84
485 45 56716 11–87 29 48 55 64 84
GFR, glomerular filtration rate.
Values are given as means (s.d.), ranges and 5th, 25th, 50th, 75th, and 95th percentile. For age classes with No10 only medians and range is given.
Table 2b | Estimated GFR in caucasian females with reported comorbidity of the Nijmegen Biomedical Study
Age (years) N Mean7s.d. Range P5 P25 P50 P75 P95
18–24 7 — 84–142 — — 102 — —
25–29 15 8179 65–101 65 73 83 85 101
30–34 33 79716 39–127 60 72 78 86 111
35–39 50 77712 51–113 58 68 76 83 92
40–44 43 79717 57–159 64 70 75 86 102
45–49 60 70715 5–90 52 64 70 78 87
50–54 101 72711 42–100 56 63 71 80 93
55–59 106 70712 28–98 51 62 70 77 91
60–64 141 67712 27–98 48 61 67 75 86
65–69 154 63714 23–111 42 53 63 72 88
70–74 166 61712 16–94 43 53 62 70 79
75–79 131 59714 26–97 36 50 59 69 86
80–84 100 56715 26–91 29 46 55 65 82
485 95 55715 21–95 29 45 53 64 82
GFR, glomerular filtration rate.
Values are given as means (s.d.), ranges and 5th, 25th, 50th, 75th, and 95th percentile. For age classes with No10 only median and range are given.
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values below 50 ml/min/1.73 m2 (age 55–74) or 40 ml/min/
1.73 m2 proved better thresholds. These figures compare
nicely with our reference values, clearly falling below the
5% percentile.
Admittedly, there is debate on the use of formulas for
estimating GFR. Newer formulas have been developed,
however, their performance compared with the MDRD
formula has been questioned. In a recent study Hallan
et al.22 showed that the MDRD formula (using calibrated
creatinine) gives nearly unbiased estimates of GFR, whereas
all other formula had a much larger negative bias especially in
the elderly.
Our study has several limitations. We have used a
questionnaire to ascertain the health status of the partici-
pants. Thus, persons who are unaware of a underlying
comorbidity may be incorrectly classified as ‘healthy’.
Participants were also asked if they had seen their family
physician or a hospital specialist within 3 or 12 months
before the study, respectively. Fifty-three percent of the study
participants denied any contact with such health-care
professionals. Limiting the analysis to this subgroup had no
major effect: only for the age groups 480 years (with few
remaining persons), the fifth percentile was higher at values
of 45 ml/min/1.73 m2. We have measured serum creatinine at
one time point only. Correct classification of CKD stage 3–5
requires decreased GFR values for a period of at least three
months. Therefore, we may have overestimated the true
prevalence of CKD stages 3–5 in our population. As our
healthy study participants had not used medication or
contacted a physician in the 3 months before the study, the
likelihood of major classification errors is small. Of note, our
data do not necessarily reflect true GFR. The seemingly lower
estimated GFR in women may thus be the consequence of the
well-known underestimation of true GFR by the MDRD
formula in women.8,23 Lastly, our data cannot be applied to
other, non-Caucasian populations.
In conclusion, we provide age- and sex-specific values of
estimated GFR using the MDRD formula with proper
calibration of creatinine. These values should allow a better
interpretation of reported GFR data of individual patients. As
such, the data should help in guiding treatment of the
individual patients.
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Figure 1 | Reference values of estimated GFR for non-diseased
Caucasian males. Median values and 5, 25, 75, and 95 percentiles are
shown for persons grouped in 5 years age classes.
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Figure 2 | Reference values of estimated GFR for non-diseased
Caucasian females. Median values and 5, 25, 75, and 95 percentiles
are shown for persons grouped in 5 years age classes.
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Figure 3 | Prevalence of CKD stages 3–5 (GFRo60 ml/min/1.73 m2)
according to age in the non-diseased Caucasian Nijmegen
Biomedical Study population. Black bars represent men and open
bars women.
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MATERIALS AND METHODS
Sample design
Details of the Nijmegen Biomedical Study have been described
before.24 In brief, the Nijmegen Biomedical Study is a population-
based cross-sectional study conducted by the Radboud University
Nijmegen Medical Centre. Approval to conduct the study was
obtained from the Institutional Review Board. Nijmegen is a town in
the eastern part of The Netherlands with 156 000 inhabitants,
approximately 87% of Caucasian descent. Age and sex stratified
randomly selected adult (age 18 years and older) inhabitants of
Nijmegen (n¼ 22 452) received an invitation to fill out a postal
questionnaire on lifestyle and medical history. The following
questions were used to collect data on pre-existent renal and
vascular disease:
‘Have you ever been diagnosed by a physician with any of the
underlying diseases: myocardial infarction, stroke or cerebrovascular
disease, diabetes, hypertension, or any kidney disease’. In addition,
specific information was gathered on the use of any drug therapy in
the last 6 months.
The response to the questionnaire was 41.7% (n¼ 9371). In
addition, 68.9% of the responders donated 2 8.5 ml blood
(n¼ 6455). No physical examination was carried out. Serum
creatinine was measured in these samples. We limited the analysis
for this paper to the 6097 Caucasian participants with valid data, of
whom 2823 were male and 3272 female. Of this population, 2365
reported an underlying condition (hypertension n¼ 1032, diabetes
n¼ 358, myocardial infarction n¼ 362, stroke n¼ 127, kidney
disease n¼ 145, or the use of diuretic, antihypertensive, or
antirheumatic drugs n¼ 347). The remaining 3732 participants
(1660 male, 2072 female) were defined as the disease-free
population.
Laboratory methods
Serum creatinine was measured by a kinetic alkaline picrate method
on an Aeroset auto-analyser of Abbott. In view of the importance of
interlaboratory and methodological differences in the creatinine
assays on results of estimated GFR creatinine data obtained by the
Jaffe method were calibrated against the Roche enzymatic creatinine
assay. We also have sent 40 serum samples to the Cleveland Clinic
Laboratory, which is the original MDRD laboratory. The Cleveland
Clinic Laboratory has measured serum creatinine using a Beckman-
modified kinetic alkaline picrate reaction.
Calculations
We observed the following relationship between the Roche
enzymatic creatinine assay and the Jaffe alkaline picrate assay,
yielding the following equation: y (Nijmegen enzymatic)¼ 1.266
(Nijmegen Jaffe)29.
Comparison between creatinine measured in our laboratory and
in the Cleveland Clinic Laboratory revealed y (creatinine Cleve-
land)¼ 1.021 (Nijmegen enzymatic)þ 11.
For calculation of GFR, we used serum creatinine values
calibrated to the original MDRD laboratory values.
GFR was calculated using the abbreviated MDRD formula:
186 (serum creatinine (in mmol/l)/88.4)1.154 (age (in years))–0.203
 0.742 (if female).
Patients were classified in stages of GFR according to the
classification of CKD as defined by the K/DOQI guidelines. Notably,
as we have no information on urinary protein excretion, we only
provide data on the prevalence of CKD stages 3–5.
We calculated means with standard deviation and 5th,
25th, 50th, 75th, and 95th percentile using STATA software
(Version 9.1).
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